SCHEMBL2804401

SCHEMBL2804401

O=C(Nc1ccccc1Cl)N1CCc2c(cnc3[nH]ncc23)C1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PAK1 Q13153 4/20 0.59
TAS1R3 Q7RTX0 4/20 0.52
TAS1R1 Q7RTX1 4/20 0.52
TAS1R2 Q8TE23 4/20 0.52
TRPV1 Q8NER1 3/20 0.51
POLB P06746 2/20 0.51
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 1/20 0.47
MAPT P10636 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
FAAH O00519 1/20 0.45
TAAR1 Q96RJ0 1/20 0.43
KIT P10721 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2804570 0.90 PAK1 (0.49) PAK1TAS1R3TAS1R1TAS1R2TRPV1
SCHEMBL2805634 0.87 KDM4E (0.61) PAK1TRPV1POLBKDM4EALDH1A1
SCHEMBL2804206 0.86 RAB9A (0.46) PAK1TAS1R3TAS1R1TAS1R2TRPV1
SCHEMBL2806132 0.86 PAK1 (0.44) PAK1TAS1R3TAS1R1TAS1R2TRPV1
SCHEMBL2486602 0.85 RAB9A (0.55) PAK1TAS1R3TAS1R1TAS1R2TRPV1
SCHEMBL2802586 0.84 FLT3 (0.47) PAK1TAS1R3TAS1R1TAS1R2TRPV1
SCHEMBL2804020 0.84 PDGFRB (0.47) PAK1TAS1R3TAS1R1TAS1R2TRPV1
SCHEMBL12342043 0.83 MEN1 (0.55) PAK1TAS1R3TAS1R1TAS1R2TRPV1
SCHEMBL2809081 0.83 KMT2A (0.43) PAK1ALDH1A1MAPTSMN1; SMN2FAAH
SCHEMBL2485492 0.82 RAB9A (0.47) PAK1TAS1R3TAS1R1TAS1R2TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 PAK1 717/4885TAS1R3 4695/4885TAS1R1 4805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.